Last reviewed · How we verify
NCT05328726
Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects
Phase 1 trial testing GZR-18 in Diabetes Mellitus, Type 2 in 24 participants. Completed in 9 March 2023.
9 February 2023
Quick facts
| Lead sponsor | Gan and Lee Pharmaceuticals, USA |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 8 March 2022 |
| Primary completion | 9 February 2023 |
| Estimated completion | 9 March 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- GZR-18 — full drug profile →
- Placebo
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
Gan and Lee Pharmaceuticals, USA — full company profile →
Who can join
Adults 18 to 60, male only, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Single ascending dose first time in human study for GZR18 in healthy subjects
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05328726
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other Gan and Lee Pharmaceuticals, USA trials
Trials by the same sponsor.
- NCT07242664 — Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State · Phase 1 · recruiting
- NCT07146347 — Comparison Study of Insulin GZR4 With Insulin Degludec · Phase 1 · recruiting
- NCT06737042 — Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants · Phase 2 · not yet recruiting
- NCT06670209 — A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochlori · Phase 1 · not yet recruiting
- NCT06547502 — Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05328726 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gan and Lee Pharmaceuticals, USA
- Last refreshed: 23 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05328726.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing